-
Atypical squamous cells in urine cytology are associated with a significant risk of high‐grade malignancy Cancer Cytopathol. (IF 3.4) Pub Date : 2024-04-13 Linh Ho, Tarik M. Elsheikh
BackgroundAtypical squamous cells (ASC) in urine cytology are rarely found, and their clinical significance is not well studied. Previous studies were limited by a small number of cases and a lack of objective grading of ASC and/or their correlation with accompanying urothelial cell abnormality (UCA).MethodsThe institutional database was searched over 10 years for urine cytology reports containing
-
Diagnostic accuracy of International System for Reporting Serous Fluid Cytopathology: A systematic review and meta‐analysis in malignancy diagnosis Cancer Cytopathol. (IF 3.4) Pub Date : 2024-04-13 Sana Ahuja, Rhea Ahuja, Shivam Pandey, Sufian Zaheer
This study conducts the first meta‐analysis to assess the aggregated risk of malignancy associated with each category of the International System for Reporting Serous Fluid Cytopathology (ISRSFC) for reporting serous effusion cytology, while also evaluating diagnostic accuracy. PubMed/MEDLINE and Embase were systematically searched using the keywords “(pleural, peritoneal, and pericardial effusions)
-
Spotlight: Rising stars in cytology Cancer Cytopathol. (IF 3.4) Pub Date : 2024-04-12 Pasquale Pisapia
-
How the Milan System for Reporting Salivary Gland Cytopathology works in cytopathology practice: Meta-analysis of prospective studies and comparison with retrospective studies Cancer Cytopathol. (IF 3.4) Pub Date : 2024-04-09 Henri Lagerstam, David Kalfert, Zahra Maleki, Ivana Kholová
The Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) is widely accepted and endorsed by professional societies. Although several studies focusing on the MSRSGC have been published, few have been prospective studies. The objective of this study was to evaluate the effectiveness of the MSRSGC in cytopathology practice.
-
Exploring the atypia of undetermined significance: Malignant ratio, ThyroSeq v3 positive call rate, molecular-derived risk of malignancy, and risk of malignancy as possible quality metric tools in thyroid cytology Cancer Cytopathol. (IF 3.4) Pub Date : 2024-04-09 Jaylou M. Velez Torres, Porshya M. Curnow, Youley Tjendra, Merce Jorda, Carmen Gomez Fernandez, Monica Garcia Buitrago, Yiqin Zuo, Roberto Ruiz Cordero
The atypia of undetermined significance (AUS) category is heterogeneous, leading to variations in its use. To prevent excessive usage, the AUS rate should be ≤10%. Although this recommendation aims to maintain diagnostic quality, it lacks supporting data. The AUS:Malignant (AUS:M) ratio has been proposed as a metric tool to evaluate AUS use. Furthermore, integrating ThyroSeq v3 (TSV3) positive call
-
Spotlight: Rising stars in cytology Cancer Cytopathol. (IF 3.4) Pub Date : 2024-04-10 Jaylou M. Velez Torres
-
Atypia of undetermined significance and ThyroSeq v3–positive call rates as quality control metrics for cytology laboratory performance Cancer Cytopathol. (IF 3.4) Pub Date : 2024-04-10 Odille Mejia‐Mejia, Andres Bravo‐Gonzalez, Monica Sanchez‐Avila, Youley Tjendra, Rodrigo Santoscoy, Katherine Drews‐Elger, Yiqin Zuo, Camilo Arias‐Abad, Carmen Gomez, Monica Garcia‐Buitrago, Mehrdad Nadji, Merce Jorda, Jaylou M. Velez‐Torres, Roberto Ruiz‐Cordero
BackgroundThe Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) recommends an upper limit of 10% for atypia of undetermined significance (AUS). Recent data suggest that this category might be overused when the rate of cases with molecular positive results is low. As a quality metric, the AUS and positive call rates for this facility’s cytology laboratory and each cytopathologist (CP) were
-
Issue Information Cancer Cytopathol. (IF 3.4) Pub Date : 2024-04-07
No abstract is available for this article.
-
Growing cancer risks on a warming planet Cancer Cytopathol. (IF 3.4) Pub Date : 2024-04-07 Bryn Nelson, William Faquin
In August 2017, unusually warm waters in the western Gulf of Mexico helped a sputtering tropical storm to re-form into what would become the most damaging hurricane in recorded Texas history. Hurricane Harvey dumped a record 52 inches of rain into Houston’s Cedar Bayou and flooded the heavily industrialized Houston Ship Canal along with the petrochemical facilities lining its banks and at least 13
-
Molecular analysis using SalvGlandDx improves risk of malignancy estimation and diagnosis of salivary gland cytopathology: An exploratory multicenter study Cancer Cytopathol. (IF 3.4) Pub Date : 2024-04-02 Sandra N. Freiberger, Kristian Ikenberg, Demi van Egmond, Sofie Claerhout, Tom van Wezel, Isabelle Vanden Bempt, Jeroen N. van Rossem, Simon A. Mueller, Paul M Clement, Vincent Vander Poorten, Danielle Cohen, Esther Hauben, Niels J. Rupp
BackgroundDiagnosis of salivary gland neoplasms is challenging, especially on cytological specimens acquired by fine‐needle aspiration. The recently implemented standardized Milan system for reporting salivary gland cytopathology provides an estimated risk of malignancy (ROM); yet, for two of the categories, the diagnosis of the lesion remains unclear. However, a precise diagnosis is desirable for
-
Papillae, psammoma bodies, and/or many nuclear pseudoinclusions are helpful criteria but should not be required for a definitive cytologic diagnosis of papillary thyroid carcinoma: An institutional experience of 207 cases with surgical follow up Cancer Cytopathol. (IF 3.4) Pub Date : 2024-04-02 Tarik M. Elsheikh, Matthew Thomas, Jennifer Brainard, Jessica Di Marco, Erica Manosky, Bridgette Springer, Dawn Underwood, Deborah J. Chute
BackgroundNoninvasive follicular thyroid neoplasm with papillary‐like features (NIFTP) was introduced in 2016 replacing noninvasive follicular variant of papillary thyroid carcinoma, with recommendations to label them “noncancer.” To avoid reducing risk of malignancy (ROM) and overdiagnosing NIFTP as malignant, some authors required restricted cytologic criteria (RC) for a definitive diagnosis of papillary
-
Thyroid nodules with DICER1 mutation or PTEN alteration: A comparative cytologic, clinical, and molecular study of 117 FNA cases Cancer Cytopathol. (IF 3.4) Pub Date : 2024-04-01 Tikamporn Jitpasutham, Stefen Andrianus, Maria Gubbiotti, Vania Nosé, Zubair W. Baloch, Emilio Madrigal, William C. Faquin
BackgroundDICER1 mutations and PTEN alterations are increasingly detected by thyroid fine‐needle aspiration (FNA). Both are associated with nodular thyroid disease and cancer. The authors analyzed a large comparative thyroid FNA cohort with DICER1 mutation or PTEN alteration.MethodsA total of 117 thyroid FNAs with DICER1 or PTEN alterations were retrieved from the databases of two academic medical
-
Risks of malignancy in the major nongynecologic cytopathology reporting systems: Critiques and discussions Cancer Cytopathol. (IF 3.4) Pub Date : 2024-03-29 Marc P. Pusztaszeri, Mauro Saieg, Zubair W. Baloch
The ever‐increasing popularity of standardized systems for reporting cytopathology has led in part to much attention to and importance of the risk stratification schemes, especially the risks of malignancy (ROMs), which are associated with the different diagnostic categories and upon which recommendations for clinical management are based. However, it is well known that the ROM calculations are based
-
The updated College of American Pathologists principles of analytic validation of immunohistochemical assays: A step forward for cytopathology Cancer Cytopathol. (IF 3.4) Pub Date : 2024-03-27 Sinchita Roy‐Chowdhuri
Updated College of American Pathologists guideline recommendations include specific guidelines for validating immunohistochemistry assays performed on cytology specimens. The new recommendations may be the impetus needed to open the door to a wider adoption of cytology specimens into routine clinical practice for immunochemistry‐based assays that drive patient care and biomarker‐driven therapeutics
-
Comprehensive evaluation of cytomorphologic, histologic, and molecular features of DICER1‐altered thyroid lesions on FNA: A multipractice experience Cancer Cytopathol. (IF 3.4) Pub Date : 2024-03-23 Krisztina Lengyel, Daniel J. Lubin, Wen‐Yu Hsiao, Sam Sirotnikov, Guangju Luo, James W. Roberts, Qiuying Shi, Kelly Magliocca, Melinda M. Lewis, Donald L. Sears, Ghulam Ilyas, Beverly B. Rogers, Kartik Viswanathan
BackgroundDICER1 mutations, though infrequent, are encountered on preoperative molecular testing of indeterminate adult and pediatric thyroid fine‐needle aspiration (FNA) specimens. Yet, published cytomorphologic features of DICER1‐altered thyroid lesions are limited. Cytomorphological features of DICER1‐altered thyroid lesions were examined in a multipractice FNA cohort with clinical, radiological
-
Incorporation of DNA methylation profiling into the cytopathology laboratory Cancer Cytopathol. (IF 3.4) Pub Date : 2024-03-16 Gloria H. Sura, Leomar Y. Ballester
CONFLICT OF INTEREST STATEMENT The authors declared no conflicts of interest.
-
Improving diagnostic yield of pancreatic serous cystadenoma with cyst fluid ancillary testing, adjunct immunohistochemistry, and additional fine‐needle biopsy sampling Cancer Cytopathol. (IF 3.4) Pub Date : 2024-03-07 Xi Wang, Xuchen Zhang, Pei Hui, Guoping Cai
BackgroundFine‐needle aspiration (FNA) diagnosis of pancreatic serous cystadenoma (SCA) remains challenging. This retrospective study aimed to evaluate the roles of cyst fluid ancillary testing and combined fine‐needle biopsy (FNB) in improving the diagnostic yield.MethodsThe authors retrospectively reviewed cytology cases that were histologically confirmed SCAs. Clinical features and FNA cyst fluid
-
Interobserver agreement in the interpretation of anal cytology Cancer Cytopathol. (IF 3.4) Pub Date : 2024-03-07 Maria Benevolo, Francesca Rollo, Alessandra Latini, Massimo Giuliani, Amalia Giglio, Eugenia Giuliani, Maria Gabriella Donà
BackgroundAnal cytology represents a tool for anal cancer screening in high‐risk populations. In addition to accuracy, the reproducibility of the interpretation is of key importance. The authors evaluated the agreement of anal cytologic interpretation between two cytopathologists.MethodsLiquid‐based cytologic slides from human immunodeficiency virus (HIV)‐negative men who have sex with men (MSM) were
-
Issue Information Cancer Cytopathol. (IF 3.4) Pub Date : 2024-03-07
No abstract is available for this article.
-
Growing threats of a mass exodus in governmental public health Cancer Cytopathol. (IF 3.4) Pub Date : 2024-03-07 Bryn Nelson, William Faquin
The backbone of the nation’s public health workforce is buckling. A recent study has raised alarms with its dire prediction of a mass exodus of governmental public health workers—considered the “backbone” of public health efforts in the United States—if current trends hold.1 “In our analytic sample, nearly half of all employees in state and local public health agencies left between 2017 and 2021, a
-
Leveraging archival cerebrospinal fluid samples for genetic insights from cell-free DNA Cancer Cytopathol. (IF 3.4) Pub Date : 2024-03-01 Alexandra M. Miller, Tejus A. Bale
Cerebrospinal fluid (CSF) samples are often a rich source of tumor-derived cell-free DNA (cfDNA), a high degree of success in detecting tumor mutations can even be achieved with archival CSF samples.
-
Interobserver agreement and risk of malignancy using the International Academy of Cytology Yokohama System for reporting breast FNA biopsy in a liquid‐based exclusive cohort Cancer Cytopathol. (IF 3.4) Pub Date : 2024-02-27 Olawunmi Folarin, David Kim, Hamza N. Gokozan, Jonas J. Heymann, Jose V. Scarpa Carniello, Lucelina Rosado, Momin T. Siddiqui, Ami Patel
BackgroundPer the College of American Pathologist’s National Breast Fine Needle Aspiration Biopsy (FNAB) Practice Survey, ∼40% of laboratories use liquid‐based cytology (LBC) for breast FNAB. The reproducibility of the International Academy of Cytology Yokohama System (YS) for reporting breast FNAB on LBC was explored.DesignBreast FNAB specimens submitted as LBC only (all ThinPrep) between January
-
Detection of effusion tumor cells under different storage and processing conditions Cancer Cytopathol. (IF 3.4) Pub Date : 2024-02-19 Diane M. Libert, Yili Zhu, Aihui Wang, Grace M. Allard, Alarice Cheng‐Yi Lowe
BackgroundCirculating tumor cells (CTCs) shed into blood provide prognostic and/or predictive information. Previously, the authors established an assay to detect carcinoma cells from pleural fluid, termed effusion tumor cells (ETCs), by employing an immunofluorescence‐based CTC‐identification platform (RareCyte) on air‐dried unstained ThinPrep (TP) slides. To facilitate clinical integration, they evaluated
-
Retrospective analysis of cytology and high‐risk HPV testing in 1067 endocervical adenocarcinomas and precursor lesions Cancer Cytopathol. (IF 3.4) Pub Date : 2024-02-19 Lei Ye, Meifu Gan, Yeli Yao, Bingjian Lu
BackgroundCytology and high‐risk human papilloma virus (hrHPV) cotesting is the mainstay in the detection of cervical carcinoma.MethodsEndocervical adenocarcinoma (EAC) is divided into HPV‐associated adenocarcinoma (HPVA) and HPV‐independent adenocarcinoma (HPVI) by the World Health Organization classification (2020). The detection effect of cotesting is suggested to be different among EAC subtypes
-
Rapid on-site evaluation of touch imprint cytology in navigation bronchoscopy for small peripheral pulmonary nodules Cancer Cytopathol. (IF 3.4) Pub Date : 2024-02-12 Stephan E. P. Kops, Lizanne J. W. van der Burgt, Shoko Vos, Lia J. M. van Zuijlen-Manders, Roel L. J. Verhoeven, Erik H. F. M. van der Heijden
Rapid on-site evaluation (ROSE) of cytopathology plays an important role in determining whether representative samples have been taken during navigation bronchoscopy. With touch imprint cytology (TIC), histologic samples can be assessed using ROSE. Although advised by guidelines, there have been almost no studies on the performance of TIC during navigation bronchoscopy. The objective of this study
-
Prediction of lymph node status in patients with surgically treated head and neck squamous cell carcinoma via neck lavage cytology: A pilot study Cancer Cytopathol. (IF 3.4) Pub Date : 2024-02-08 Hugo Rimbach, Maximilian Linxweiler, Sandrina Körner, Sigrun Smola, Barbara Linxweiler, Stefanie Speicher, Johanna Helfrich, Erich-Franz Solomayer, Mathias Wagner, Bernhard Schick, Jan Philipp Kühn
Neck dissection is a standardized surgical procedure for patients with head and neck squamous cell carcinoma (HNSCC) and plays a critical role in the choice of adjuvant treatment based on histopathological findings. Saline irrigation is routinely performed at the end of surgery. However, this irrigant is not used for diagnostic purposes.
-
Urine cytology in the detection of renal cell carcinomas – a territory-wide multi-institutional retrospective review of more than 2 decades Cancer Cytopathol. (IF 3.4) Pub Date : 2024-02-08 Joshua J. X. Li, Joanna K. M. Ng, Cheuk-Yin Tang, Bryan C. H. Chan, Sau Yee Chan, Jasmine H. N. Law, Jeremy Y. Teoh, Christopher J. VandenBussche, Gary M. Tse
Compared with urothelial lesions of the upper urinary tract, the diagnostic performance of urine cytology in detection of renal cell carcinomas is underreported. This study aims to establish the role of urine cytology in the assessment of renal carcinomas by a multi-institute review of urine cytology from nephrectomy confirmed renal cell carcinomas, referenced against renal urothelial and squamous
-
Performance of a multigene genomic classifier and clinical parameters in predicting malignancy in a Southeast Asian cohort of patients with cytologically indeterminate thyroid nodules Cancer Cytopathol. (IF 3.4) Pub Date : 2024-02-06 Samantha Peiling Yang, Min En Nga, Manish Mahadeorao Bundele, Simion I. Chiosea, Sze Hwa Tan, Jeffrey H. Y. Lum, Rajeev Parameswaran, Ming Yann Lim, Hao Li, Wei Keat Cheah, Kathleen Su-Yen Sek, Andre Teck Huat Tan, Thomas Kwok Seng Loh, Kee Yuan Ngiam, Wee Boon Tan, Xinyong Huang, Thomas Wai Thong Ho, Keng Hua Lim, Chwee Ming Lim, Reyaz M. Singaporewalla, Anil Dinkar Rao, Nandini C. L. Rao, Dennis
Most thyroid nodules are benign. It is important to determine the likelihood of malignancy in such nodules to avoid unnecessary surgery. The primary objective of this study was to characterize the genetic landscape and the performance of a multigene genomic classifier in fine-needle aspiration (FNA) biopsies of cytologically indeterminate thyroid nodules in a Southeast Asian cohort. The secondary objective
-
Cell block practices in European cytopathology laboratories Cancer Cytopathol. (IF 3.4) Pub Date : 2024-02-07 Irena Srebotnik Kirbis, Ivana Kholova, Heini Huhtala, Massimo Bongiovanni, Margareta Strojan Flezar, Chantell Hodgson, Beatrix Cochand-Priollet
There are numerous methods and procedures described for the preparation of cell blocks (CBs) from cytological samples. The objective of this study was to determine current practices and issues with CBs in European laboratories.
-
Diagnosing medullary thyroid carcinoma is facilitated by measuring calcitonin in FNA washout fluids: Alea iacta est Cancer Cytopathol. (IF 3.4) Pub Date : 2024-02-07 Pierpaolo Trimboli, Anna Crescenzi
The prognosis for patients diagnosed with medullary thyroid carcinoma (MTC) varies significantly with the timing of detection: the earlier the diagnosis, the higher the likelihood of achieving a complete cure (or at least a better outcome). Ogmen et al. show that the routine measurement of calcitonin in serum could lead to an earlier MTC diagnosis.
-
Droplet digital polymerase chain reaction detection of KRAS mutations in pancreatic FNA samples: Technical and practical aspects for routine clinical implementation Cancer Cytopathol. (IF 3.4) Pub Date : 2024-02-03 Yara Mansour, Mehdi Boubaddi, Typhaine Odion, Marion Marty, Geneviève Belleannée, Arthur Berger, Clément Subtil, Christophe Laurent, Sandrine Dabernat, Samuel Amintas
Pancreatic adenocarcinoma (PDAC) is associated with a 5-year survival rate of less than 6%, and current treatments have limited efficacy. The diagnosis of PDAC is mainly based on a cytologic analysis of endoscopic ultrasound–guided fine-needle aspiration (EUS-FNA) samples. However, the collected specimens may prove noncontributory in a significant number of cases, delaying patient management and treatment
-
Issue Information Cancer Cytopathol. (IF 3.4) Pub Date : 2024-02-03
No abstract is available for this article.
-
Heightened but variable COVID-19 risks for patients with cancer Cancer Cytopathol. (IF 3.4) Pub Date : 2024-02-03 Bryn Nelson, William Faquin
Four years into the coronavirus disease 2019 (COVID-19) pandemic, multiple studies have agreed that patients with cancer are more susceptible to COVID-19 infection and have a higher risk of worse outcomes than the general population. Large cohort studies have revealed plenty of nuances, however, while raising additional questions in need of better answers. Some cancer types, such as hematologic malignancies
-
Cytologic risk stratification of medullary thyroid carcinoma: Does it make the grade? Cancer Cytopathol. (IF 3.4) Pub Date : 2024-02-02 Michiya Nishino
Recent efforts to develop a histologic grading system for medullary thyroid carcinoma is gaining broad acceptance. How well do these grading parameters translate to cytology specimens?
-
Implementation of The Paris System for Reporting Urine Cytology improves diagnostic accuracy of selective upper urinary tract cytology Cancer Cytopathol. (IF 3.4) Pub Date : 2024-01-31 Kosuke Miyai, Misaki Nakayama, Shinya Minabe, Sho Ogata, Keiichi Ito, Susumu Matsukuma
The Paris System for Reporting Urine Cytology (TPS) recommends diagnostic criteria for urinary tract cytology, focusing primarily on the detection of high-grade urothelial carcinoma (HGUC) in the lower urinary tract. The second edition of TPS (TPS 2.0), published in 2022, extends these recommendations to the upper urinary tract (UUT); however, there is a lack of comprehensive data on this subject.
-
Issue Information Cancer Cytopathol. (IF 3.4) Pub Date : 2024-01-01
No abstract is available for this article.
-
Fine-needle aspiration of amyloidoma: A critical analysis Cancer Cytopathol. (IF 3.4) Pub Date : 2024-01-04 Nisha S. Ramani, Bhuvaneswari Krishnan
Amyloid, presenting as a mass, is termed amyloidoma. Among the reported cases, fine-needle aspiration (FNA) of amyloid is often misinterpreted as acellular nondiagnostic material.
-
Generic cancer drugs are still in short supply Cancer Cytopathol. (IF 3.4) Pub Date : 2024-01-01 Bryn Nelson, William Faquin
Generic carboplatin and cisplatin are inexpensive and indispensable. The platinum-based, injectable chemotherapeutic drugs have factored prominently in curative regimens and combination therapies that have significantly extended patients’ lives. By rights, they should be the poster children of cost-effective cancer care. Instead, they have become the focal points of a painful drug shortage in the United
-
Challenging the concept of “risk of malignancy” in cytology Cancer Cytopathol. (IF 3.4) Pub Date : 2023-12-21 Ilias P. Nikas, Ricella Souza da Silva, Bernardo Sousa-Pinto, Fernando Schmitt
Several standardized systems for nongynecological cytopathology have been published following the successful implementation of The Bethesda System for Reporting Cervical Cytology. Each of these systems comprises a set of reporting categories accompanied by a risk of malignancy. However, in most cases, these risk of malignancy estimates have not been based on high-quality evidence and often may not
-
Issue Information Cancer Cytopathol. (IF 3.4) Pub Date : 2023-12-09
No abstract is available for this article.
-
An uncertain balance: In search of the sweet spot for cancer screening Cancer Cytopathol. (IF 3.4) Pub Date : 2023-12-09 Bryn Nelson, William Faquin
After decades of aggressive cancer treatments, multiple studies have forced a reckoning of overtreatment for low-risk prostate, cervical, breast, and other cancers. Some studies of patients with low-risk prostate cancer managed by active surveillance, for example, have reported 10-year prostate cancer-specific survival rates of nearly 100%. A 2015 study, by contrast, found that of roughly 3000 men
-
Grading medullary thyroid carcinoma on fine-needle aspiration cytology specimens with the International Medullary Thyroid Carcinoma Grading System: A cytologic–histologic correlation Cancer Cytopathol. (IF 3.4) Pub Date : 2023-12-08 Kartik Viswanathan, D. Blake Behrman, Daniel J. Lubin
Medullary thyroid carcinoma (MTC) is a rare cancer of parafollicular C-cell origin. The International MTC Grading System (IMTCGS) incorporates mitotic activity, the presence of necrosis, and the Ki67 proliferation rate (PR) to classify MTCs as low or high grade. The ability to predict IMTCGS grade in cytology was assessed.
-
Comprehensive evaluation of benign and malignant etiologies of different serous effusions with the International System for Reporting Serous Fluid Cytopathology: A multi-institutional study in Taiwan Cancer Cytopathol. (IF 3.4) Pub Date : 2023-12-08 Chun-Han Lu, Chih-Yi Liu, Jie-Yang Jhuang, Chien-Chin Chen
The International System for Reporting Serous Fluid Cytopathology (ISRSFC) was introduced globally in 2019 in response to the absence of a standardized reporting system for serous fluid cytology. This study presents experiences implementing this system across three distinct hospitals in Taiwan.
-
The diagnostic utility of methylthioadenosine phosphorylase immunohistochemistry for pancreatic ductal adenocarcinoma in FNA and small biopsy specimens Cancer Cytopathol. (IF 3.4) Pub Date : 2023-12-06 Sanhong Yu, Leona A. Doyle, Jason L. Hornick, Jeffrey K. Mito
Accurate diagnosis of pancreatic lesions by endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) or fine-needle biopsy can be challenging. Although surrogate immunohistochemical markers for genetic alterations associated with pancreatic ductal adenocarcinoma (PDAC) have been identified, they have modest sensitivity. Biallelic loss of CDKN2A occurs in up to 46% of PDACs, and methylthioadenosine
-
Efficacy of Cobas HPV testing for predicting grade 2+ cervical intraepithelial neoplasia in a cancer prevention center and a gynecologic oncology clinic: A single-institution experience Cancer Cytopathol. (IF 3.4) Pub Date : 2023-12-06 Elizabeth Davaro, Agata A. Tinnirello, Therese B. Bevers, Andrea Milbourne, Roland Bassett, John Stewart, Ming Guo
To evaluate the efficacy of Cobas human papillomavirus (HPV) testing to predict cervical intraepithelial neoplasia of grade 2 or higher (CIN2+), Cobas HPV testing results were correlated with follow-up biopsy in patients from Cancer Prevention Center (CPC) and Gynecologic Oncology Clinic (GOC) of The University of Texas MD Anderson Cancer Center.
-
Sensitivity of urine cytology in detecting high-grade urothelial carcinoma in patients with neoplastic urinary bladder diverticula: A major cancer center experience Cancer Cytopathol. (IF 3.4) Pub Date : 2023-12-06 Mohamed Alhamar, Hikmat A. Al-Ahmadie, Rusmir Feratovic, Oscar Lin
Bladder diverticula are herniations of bladder urothelium and mucosa through the muscularis propria. The reported incidence of neoplasia arising in bladder diverticula is widely variable. The authors’ objective was to study the characteristics and sensitivity of urine cytology in these patients with emphasis on primary intradiverticular bladder cancer (IDBC).
-
Correlation of immediate prevalence of cervical precancers and cancers with HPV genotype and age in women with atypical glandular cells cytology: A retrospective analysis of 369 cases Cancer Cytopathol. (IF 3.4) Pub Date : 2023-11-20 Xin Zhou, Wanrun Lin, Yiming Qin, Jing Zhang, Xiaofei Zhang, Huijuan Zhang, Wenxin Zheng, Feng Zhou
This study aims to assess the immediate risk of cervical precancers and cancers in women with atypical glandular cells (AGC) cytology, based on high-risk human papillomavirus (hrHPV) genotypes and age.
-
Second edition of the Milan System for Reporting Salivary Gland Cytopathology: Refining the role of salivary gland FNA Cancer Cytopathol. (IF 3.4) Pub Date : 2023-11-16 Esther Diana Rossi, Zubair Baloch, Guliz Barkan, Maria Pia Foschini, Daniel Kurtycz, Marc Pusztaszeri, Philippe Vielh, William C. Faquin
The use of standardized reporting systems for non-gynecologic cytopathology has made enormous gains in popularity during the past decade, including for thyroid fine-needle aspiration, urine cytology, serous effusions, pancreas, lymph nodes, lung, and more. In February 2018, the first edition Atlas of the Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) was published. The MSRSGC defines
-
Diagnostic terminology for benign/low-risk tumors on renal cytology Cancer Cytopathol. (IF 3.4) Pub Date : 2023-11-10 Andrew A. Renshaw, Martha B. Pitman
Biopsy of benign and low-risk tumors of the kidney can be grouped into three distinct categories with different levels of risk, and the suggested diagnoses of these tumors should be tailored to their respective category.
-
An old friend, a new insight: Calcitonin measurement in serum and aspiration needle washout fluids significantly increases the early and accurate detection of medullary thyroid cancer Cancer Cytopathol. (IF 3.4) Pub Date : 2023-11-10 Berna Evranos Ogmen, Nurcan Ince, Aysegul Aksoy Altınboga, Leyla Akdogan, Sefika Burcak Polat, Birgul Genc, Ebru Menekse, Cevdet Aydin, Oya Topaloglu, Reyhan Ersoy, Bekir Cakir
The sensitivity of cytological (CY) evaluation after fine-needle aspiration (FNA) for detecting medullary thyroid carcinoma (MTC) is a subject of controversy. The routine use of serum calcitonin (CT) in patients with thyroid nodules is not universally adopted. The authors conducted CT screening of FNA washout fluid (FNA-CT) to address the diagnostic challenges. The objective was to assess the contributions
-
Issue Information Cancer Cytopathol. (IF 3.4) Pub Date : 2023-11-01
No abstract is available for this article.
-
The unexpected costs of “free” preventive care Cancer Cytopathol. (IF 3.4) Pub Date : 2023-11-01 Bryn Nelson, William Faquin
This news section is written by a medical journalist and offers Cancer Cytopathology readers timely information on events, issues, and personalities of interest to the subspecialty. In this issue, the first of a two-part series on the struggle to balance preventive care costs and benefits. Federal laws have directed insurers to offer free cancer screening, but loopholes and uneven implementation have
-
Erratum to “p53 expression in cytology samples may represent a marker of early-stage cancer” Cancer Cytopathol. (IF 3.4) Pub Date : 2023-10-21
This erratum corrects the following: Policardo F, Tralongo P, Arciuolo D, et al. p53 expression in cytology samples may represent a marker of early-stage cancer. Cancer Cytopathol. 2023;131(6):392-401. doi:10.1002/cncy.22694 Please note that the surname of one of the authors, Lina Cardisciani, was misspelled as “Cardasciani.” The authors regret this error.
-
Thank You to Reviewers 2023 Cancer Cytopathol. (IF 3.4) Pub Date : 2023-10-18
Cancer Cytopathology’s reputation is determined by the quality of the manuscripts submitted and the expertise, dedication, and promptness of the individuals who critically review the manuscripts. In this issue, we’d like to congratulate and acknowledge our top reviewers for their outstanding peer review efforts from the period spanning from September 1, 2022, through August 31, 2023. These individuals
-
Bridging the gap to the next generation of learners and column leadership. Cancer Cytopathol. (IF 3.4) Pub Date : 2023-10-17 Diane Davis Davey,Sara E Monaco
-
Molecular-derived risk of malignancy and the related positive call rate of indeterminate thyroid cytology diagnoses as quality metrics for individual cytopathologists Cancer Cytopathol. (IF 3.4) Pub Date : 2023-10-17 N. Paul Ohori, Jacqueline M. Cuda, Sheldon I. Bastacky, Linwah Yip, Esra Karslioglu-French, Elena M. Morariu, Jagdeesh Ullal, Kimberly M. Ramonell, Sally E. Carty, Yuri E. Nikiforov, Karen E. Schoedel, Raja R. Seethala
Indeterminate thyroid cytopathology diagnoses represent differing degrees of risk that are corroborated by follow-up studies. However, traditional cytologic–histologic correlation may overestimate the risk of malignancy (ROM) because only a subset of cases undergo resection. Alternatively, some molecular tests provide probability of malignancy data to calculate the molecular-derived risk of malignancy
-
Unlocking the potential of organoids in cancer treatment and translational research: An application of cytologic techniques Cancer Cytopathol. (IF 3.4) Pub Date : 2023-10-16 Mohamed A. Abd El-Salam, Maria J. Troulis, Chong-Xian Pan, Rema A. Rao
Patient-derived organoid models hold promise for advancing clinical cancer research, including diagnosis and personalized and precision medicine approaches, and cytology, in particular, plays a pivotal role in this process. These three-dimensional multicellular structures are heterogeneous, potentially maintain the cancer phenotype, and conserve the genomic, transcriptomic, and epigenomic patterns
-
Fine-needle aspiration biopsy of axillary lymph nodes: A reliable diagnostic tool for breast cancer staging Cancer Cytopathol. (IF 3.4) Pub Date : 2023-10-16 Luai Sallout, Mohamed Tashkandi, Amani Moqnas, Hebah AlMajed, Abdulrhman Al-Naeem, Yazeed Alwelaie
Pathologic evaluation of sentinel lymph node biopsy (SLNB) samples is crucial for axillary staging in patients newly diagnosed with breast cancer. Patients with pathologic evidence of nodal metastasis scheduled for upfront surgery typically also undergo axillary lymph node dissection (ALND). Although SLNB is the gold standard method for detecting nodal metastasis, axillary lymph node fine-needle aspiration
-
Urinary IL-6 and IL-8 as predictive markers in bladder urothelial carcinoma: A pilot study Cancer Cytopathol. (IF 3.4) Pub Date : 2023-10-09 Christopher J. VandenBussche, Christopher D. Heaney, Max Kates, John J. Hooks, Kelly Baloga, Lori Sokoll, Dorothy Rosenthal, Barbara Detrick
Cytokines are known to be a key a factor in numerous malignancies and to exert an important regulatory role in the tumor microenvironment. Interest has grown in understanding how cytokines modulate the tumor microenvironment and which cytokines may serve as markers of the tumor process; however, a complete picture of the cytokine landscape in bladder cancer remains unclear.
-
Validation of targeted next-generation sequencing of cell-free DNA from archival cerebrospinal fluid specimens for the detection of somatic variants in cancer involving the leptomeninges: Cytopathologic and radiographic correlation Cancer Cytopathol. (IF 3.4) Pub Date : 2023-10-09 Alexander J. Neil, Ugonma N. Chukwueke, Nicholas Hoover, Sean R. N. Marris, Vanesa Rojas-Rudilla, Danielle K. Manning, Jeffrey K. Mito, Edmund S. Cibas, Lynette M. Sholl
Leptomeningeal metastases occur across multiple solid and lymphoid cancers, and patients typically undergo cytopathologic assessment of cerebrospinal fluid (CSF) in this setting. For patients diagnosed with metastatic cancer, the detection of actionable somatic mutations in CSF can provide clinically valuable information for treatment without the need for additional tissue collection.